Roche reports positive results from Phase III trial of perjeta combination therapy in breast cancer

Roche has reported positive results from the Phase III (APHINITY) clinical trial of perjeta (pertuzumab) in combination with herceptin (trastuzumab) and chemotherapy for the treatment of patients with breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news